Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.

Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE. · 2020

Read Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. by Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7199908.txt.

Introduction

Yin and co-authors reveal how the drug remdesivir jams the copying machine of SARS-CoV-2. Their study appeared in Science. The machine, an RNA-dependent RNA polymerase, builds new copies of the viral genome. Stopping it should stop the virus from multiplying. The team captured the polymerase's structure at work.

They imaged the enzyme bound to RNA and to remdesivir. The drug mimics a natural RNA building block. Once inserted, it becomes chemically linked into the growing RNA strand. That insertion stalls further copying. The structure explains the drug's action at atomic detail. It also guides the design of better polymerase blockers. Such drugs remain a central hope against coronaviruses.

Catalog record

CREATORYin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE36 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7199908

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir By Wanchao Yin, Chunyou Mao, Xiaodong Luan, Dan-Dan Shen, Qingya Shen, Haixia Su, Xiaoxi Wang, Fulai Zhou, Wenfeng Zhao, Minqi Gao, Shenghai Chang, Yuan-Chao Xie Published in: Science (New York, N.y.) DOI: 10.1126/science.abc1560 ABSTRACT A wrench in the works of COVID-19 Understanding the inner workings of the virus that causes coronavirus disease 2019 (COVID-19) may help us to disrupt it. Yin et al. focused on the viral polymerase essential for replicating viral RNA. They determined a structure of the polymerase bound to RNA and to the drug remdesivir. Remdesivir mimics an RNA nucleotide building block and is covalently linked to the replicating RNA, which blocks further synthesis of RNA. The structure provides a template for designing improved therapeutics against the viral polymerase. Science, this issue p. 1499 The coronavirus disease 2019 (COVID-19) pandemic that has arisen from widespread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a humanitarian crisis, with more than 1.5 million infections and 87,000 deaths reported on 8 April 2020 (1, 2). These numbers have increased rapidly to more than 2.99 million infections and 207,000 deaths as of 27 April of 2020 (2). SARS-CoV-2 is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) and several members of the betacoronavirus family, including bat and pangolin coronaviruses (3–5). Compared with the binding behavior of other coronaviruses, however, the spike protein of SARS-CoV-2 has a stronger binding affinity for the host receptor (6–10), which may explain why SARS-CoV-2 has a much higher incidence of human-to-human transmission, resulting in infections throughout the world. SARS-CoV-2 is a positive-strand RNA virus. Its replication is mediated by a multisubunit replication-and-transcription complex of viral nonstructural proteins (nsps) (11). The core component of this complex is the catalytic subunit (nsp12) of an RNA-dependent RNA polymerase (RdRp) (12, 13). By itself, nsp12 has little activity and its functions require accessory factors, including nsp7 and nsp8 (14, 15), that increase RdRp template binding and processivity. RdRp is also proposed to be the target of a class of antiviral drugs that are nucleotide analogs; this category includes remdesivir (16–18), which is a prodrug that is converted to the active drug in the triphosphate form [remdesivir triphosphate (RTP)] within cells (19). As such, RdRp has been the subject of intensive structural biology efforts. The structures of nsp7, nsp8, and the complex of nsp12-nsp7-nsp8 have been determined (15, 20–23), providing the overall architecture of the RdRp complex. However, the drug discovery effort is hampered because the structures of the SARS-CoV-2 RdRp in complex with an RNA template and with nucleotide inhibitors are not known. In this study, we determined two cryo–electron microscopy (cryo-EM) structures of the SARS-CoV-2 RdRp complex: one in the apo form and the other in a complex with a template-primer RNA and the antiviral drug remdesivir. For cryo-EM studies, we coexpressed nsp12 with nsp7 and nsp8 to form the core RdRp complex in insect cells (Fig. 1A and fig. S1, A to D). The stoichiometric amount of nsp7 and nsp8 appeared to be less than that of nsp12, and thus additional bacterially expressed nsp7 and nsp8 were supplemented before the final purification step to improve the yield of heterotrimeric complex. The purified nsp12 alone showed little activity in binding to a 50-base partial double-stranded template-primer RNA (Fig. 1B and fig. S1E), which is similar to the SARS-CoV nsp12 (14). The presence of nsp7 and nsp8 markedly increased nsp12 binding to the template-primer RNA (fig. S1E). The nsp12-nsp7-nsp8 complex also showed RNA polymerization activity on a poly-U template upon addition of adenosine triphosphate (ATP) (Fig. 1, B and C). This RNA polymerization activity was effectively inhibited by the addition of RTP (Fig. 1D). Even in the presence of 10 mM ATP, which is within the range of physiological concentrations of ATP, 1 mM RTP completely inhibited RdRp polymerization activity. In addition, 100 µM RTP completely blocked the full extension but allowed partial extension of the primer RNA (Fig. 1D), consistent with a delayed chain termination mechanism (24). However, this mechanism is dependent on low RTP concentrations and low RTP/ATP ratios. By contrast, 5 mM remdesivir (as a prodrug) had no inhibitory effect on the polymerization activity of the purified enzyme (fig. S1F), nor did remdesivir in its monophosphate form (RMP) (fig. S1G). [Figure: Assembly of an active nsp12-nsp7-nsp8 RdRp complex and its inhibition by remdesivir.(A) Schematic diagram for the components of the RdRp complex, containing nsp12, nsp7, and nsp8. The polymerase motif (A to G) and the β hairpin specific to SARS-CoV-2 are highlighted. (B) Sequence of the RNA duplex with a 5′ U10 overhang as a template for primer extension and RdRp-RNA complex assembly. (C) The recombinant RdRp complex shows polymerase activity in vitro. The primer strand is labeled with fluorescence at the 5′ end. (D) Elongation of the partial RNA duplex by the purified RdRp complex and its inhibition by RTP.] The purified RdRp complex is relatively thermostable, with a melting temperature of 53°C (fig. S1H). Negative-stain EM visualization of the nsp12-nsp7-nsp8 complex displayed monodispersed particles with excellent homogeneity (fig. S1I). For the apo nsp12-nsp7-nsp8 complex, we vitrified the sample in the presence of the detergent DDM. The initial attempt at image processing revealed that the particles are preferentially oriented (fig. S2A). Therefore, we collected >7400 micrograph movies of more than 5.7 million particle projections to increase the number of projections from the nonpreferential orientation. Of these, 81,494 particles were used to yield a density map of 2.8-Å resolution (fig. S2, B and E). Cryo-EM studies of the nsp12-nsp7-nsp8 complex bound with the template-primer RNA and RTP (termed the template-RTP RdRp complex) faced two challenges (fig. S3). First, most particles were adsorbed to cryo-EM grid bars rather than staying in the vitreous ice. Second, the RNA duplex was dissociated from the template-RTP RdRp complex, likely owing to conditions of cryo-EM specimen preparation. Eventually, we prepared the cryo-EM specimen of the template-RTP RdRp complex at 15 mg/ml, which is much higher than the normal concentrations used for EM studies of soluble protein complexes. The high concentration of the complex has a mass action effect to stabilize the RNA-protein complex and has an excess amount of the complex to escape the absorption of cryo-EM grid bars to enter the vitreous ice (fig. S3). We collected 2886 micrograph movies, which yielded a 2.5-Å resolution structure using 130,386 particle projections. Because of the relatively high resolution of our structure, the EM map is clear for key structural features across the complex (fig. S4, A to F). The structure of the apo RdRp complex contains one nsp12, one nsp7, and two nsp8 proteins, with an overall arrangement resembling those seen in SARS-CoV and the recently solved structure of SARS-CoV-2 (15, 23) (Fig. 2, A and B). Our structure, which differs from the SARS-CoV RdRp structure but is similar to the recent SARS-CoV-2 RdRp structure, reveals that nsp12 also contains an N-terminal β hairpin (residues 31 to 50) and an extended nidovirus RdRp-associated nucleotidyl-transferase domain (NiRAN; residues 115 to 250) (24) with seven helices and three β strands (15, 23). After the NiRAN domain is an interface domain (residues 251 to 365), composed of three helices and

Read the complete text